Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Trodelvy (sacituzumab govitecan-hziy)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Everest Medicines, Gilead

Drug class:

Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate

Related drugs:

‹

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

›

No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	sacituzumab govitecan-hziy Sensitive: B - Late Trials sacituzumab govitecan-hziy Sensitive : B	sacituzumab govitecan-hziy Sensitive: B - Late Trials sacituzumab govitecan-hziy Sensitive : B
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria sacituzumab govitecan-hziy Sensitive : C2	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria sacituzumab govitecan-hziy Sensitive : C2
BRCA1 mutation	Endometrial Cancer	BRCA1 mutation	Endometrial Cancer	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials rucaparib + sacituzumab govitecan-hziy Sensitive : C3	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials rucaparib + sacituzumab govitecan-hziy Sensitive : C3
TP53 mutation + MDM2 mutation	Urothelial Cancer	TP53 mutation + MDM2 mutation	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: C3 – Early Trials sacituzumab govitecan-hziy Sensitive : C3	sacituzumab govitecan-hziy Sensitive: C3 – Early Trials sacituzumab govitecan-hziy Sensitive : C3
MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Resistant: C4 – Case Studies sacituzumab govitecan-hziy Resistant : C4	sacituzumab govitecan-hziy Resistant: C4 – Case Studies sacituzumab govitecan-hziy Resistant : C4
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive : C4	fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive : C4
TROP2 overexpression	Triple Negative Breast Cancer	TROP2 overexpression	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 expression	Cervical Cancer	TROP2 expression	Cervical Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 overexpression	Endometrial Cancer	TROP2 overexpression	Endometrial Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 positive	Triple Negative Breast Cancer	TROP2 positive	Triple Negative Breast Cancer	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D
RAB5A expression	HER2 Positive Breast Cancer	RAB5A expression	HER2 Positive Breast Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D
TROP2 expression	Gastric Cancer	TROP2 expression	Gastric Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D	sacituzumab govitecan-hziy Sensitive: D – Preclinical sacituzumab govitecan-hziy Sensitive : D